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ABSTRACT
Despite the increasing prevalence of Alzheimer’s disease (AD), efforts to
establish a definitive treatment or cure have met with little success. Many previous
therapeutic strategies for AD have focused on the aggregation and accumulation
of amyloid-b (Ab) in the brain, concentrating on its small intermediate aggregates
as the primary targets to ameliorate neurotoxicity and damage. This approach has
yielded little progress, and more recent discussions have shifted to strategies
geared toward a multifaceted pathology, with chronic neuroinflammation emerging
as an important factor in the disease etiology and progression.
The receptor for advanced glycation end-products, or RAGE, is a key
pattern recognition receptor of the innate immune response that represents a
broader and more integrated therapeutic target for both AD and chronic
neuroinflammation. Observations that Ab is a ligand for RAGE implicate RAGE as
a therapeutic target for AD, and RAGE has been proposed as a pathological vector
in multiple inflammatory mechanisms associated with Ab.

In addition,

RAGE-mediated signaling is relevant in the progression of diseases that represent
an increased risk in AD, such as Type II diabetes and cardiovascular disease, and
RAGE potentiates and perpetuates chronic inflammation associated with aging.
Because upregulation of transmembrane RAGE requires persistent inflammatory
insult, quantifying levels of transmembrane RAGE expression is one avenue
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through which potential AD therapeutics and inhibitors may be evaluated within the
context of chronic inflammation.
This research first develops an in vitro cellular model that utilizes RAGE
expression

and

the

concurrent

inflammatory

response

to

simulate

immunosenescence, the dysfunctional cellular inflammatory response associated
with aging. In this model, human THP-1 macrophages are exposed to a chronic
low-level pro-inflammatory stimulus for 3 days and examined for the effect of
inflammatory cytokine buildup on subsequent cytokine response to acute insult, as
well as transmembrane RAGE expression. Mimicry of key aspects of
immunosenescence such as abnormal cytokine response to inflammatory stimuli
and controlled upregulation of transmembrane RAGE are achieved; use of this
model facilitates exploration of potential therapeutics within the context of chronic
and age-associated inflammation.
Next, this model is applied to the investigation of a rationally-designed
achiral peptoid mimic of the KLVFF hydrophobic core of Ab, JPT1a. Previous study
established that JPT1a modulates Ab1-40 aggregation and alters the morphology
of the aggregates formed. This study first shows that co-incubation of a low-dose
proinflammatory stimulus with JPT1a attenuates both transmembrane RAGE
upregulation

and

associated

inflammatory

cytokine

production

in

a

dose-dependent manner. Next, the capacity of JPT1a to reverse RAGE
upregulation and reduce pro-inflammatory response in previously-stimulated cells
was examined. Treatment with JPT1a produced a significant reduction in RAGE
expression relative to untreated cells, although no significant effect on cytokine
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production was noted. Finally, cells treated with JPT1, the chiral analogue of
JPT1a, demonstrated a similar capacity to modulate transmembrane RAGE
expression to that observed with JPT1a; co-incubation of a chronic inflammatory
stimulus with JPT1 also reduced the concurrent pro-inflammatory cytokine
response.
Finally, selectivity of RAGE and JPT1a was confirmed through modified
colorimetric ELISA. A low-nanomolar binding affinity of JPT1a-RAGE was
determined via colorimetric ELISA and the Cheng-Prussoff method. Here, we
introduce a multifaceted potential therapeutic that modulates transmembrane
RAGE expression and chronic inflammation. The binding affinity observed for
JPT1A-RAGE is a full 5-to-10 fold lower than that reported for Azeliragon, the only
RAGE antagonist that has entered clinical trials. These data support the continued
investigation of JPT1a as a potential therapeutic for AD.
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CHAPTER 1:
BACKGROUND AND SIGNIFICANCE
1.1 The Challenge in Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative amyloidosis
that affects 5.8 million Americans and is the 6th leading cause of death in the United
States.1 Despite its increasing prevalence, therapeutic strategies to date have met
with little success. Moreover, the precise etiology and mechanistic progression of
AD has proven elusive despite decades of research.1
Amyloidosis is a phenomenon intrinsic to many diseases that suffer from a
lack of compelling treatment options.2 While the proteins unique to each
amyloidosis share little homology, each monomer self-assembles to form a
characteristic

b-sheet

structure,

and

these

amyloid

aggregates

or

aggregate-intermediates are frequently toxic to the local cellular environment.3–8
AD is defined through the aggregation and deposition of amyloid-b (Ab), a
cleavage product of amyloid precursor protein (APP) via b- and g-secretase at the
N- and C-terminal, respectively. As with the proteins fundamental to other
amyloidoses, monomeric Ab and its generative secretases may demonstrate
physiological relevance at low (picomolar) ranges; Ab functions in synaptic
processing, learning, and memory.9–11 Further study indicates that Ab1-42
modulates synaptic signaling through multiple pre- and post-synaptic mechanisms
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in a time- and concentration-dependent manner.10 Because of its potential benefit,
wholesale abolition of Ab production is undesirable.
Ab has thus far been viewed as the primary pathological target for AD. Per
the “Ab cascade hypothesis”, an over-abundance of monomeric Ab in the local
environment provokes nucleation, aggregation and, ultimately, fibril formation
deposited in the extracellular matrix of the brain as plaques. The toxicity of
intermediate Ab aggregates is well-established, as soluble oligomers provoke
inflammatory response and the formation of reactive oxygen species (ROS) that
contribute to progressive neuronal loss and atrophy.12 Monomeric Ab may be a
relevant and non-damaging species, and aggregation to form toxic species occurs
in the extracellular environment; therefore targeting the formation and activity of
soluble Ab oligomers outlines a therapeutic strategy that provides excellent return
at minimal expense to the physiological milieu.
Yet the exact mechanism of neuronal degradation is much debated, and
amyloid deposition does not correlate with cognitive decline. This debate has been
compounded by the lack of success of the Ab42 vaccine: long-term (and postmortem) studies showed that while the vaccine effectively removed the Ab42
plaques from patients’ brains, this removal did not halt nor slow the progression of
the disease despite elevated Ab42 antibodies in patient blood serum titers up to the
time of death.13 If Ab were truly the sole instigator of this disease, removal of this
agent should have attenuated cognitive decline, yet the opposite appeared to
occur.

While the result was not statistically significant, Holmes reports that

“participants in the study with high antibody titres had a more rapid clinical
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progression than did those with moderate antibody titres” (emphasis added).13
More recent therapeutics comprised of anti-amyloid monoclonal antibodies (mAbs)
such as bapineuzumab and solanezumab have also been largely ineffective.14
However, because of Ab’s well-established role in familial AD it remains likely that
Ab contributes to the overall disease etiology in some way.15

1.2 Inflamm-aging in Alzheimer’s Disease
The immunological changes that accompany aging include chronic
low-level systemic inflammation in the absence of infection, described as
“inflamm-aging”. This pro-inflammatory phenotype evolves over time and with
chronic exposure to molecular stress to contribute to the evolution of many agerelated illnesses, including AD.16,17 For example, the cumulative effects of diet and
lifestyle may contribute to an elevation in the basal inflammatory state, such as the
increased microglial populations observed with high-fat diet, along with elevated
TNF-α levels directly associated with this increase.18 Heightened microglial
sensitivity potentially narrows the “therapeutic dose” of microglial activation,
increasing the likelihood that any microglial activation will quickly exceed the
beneficial threshold that invokes phagocytosis, and amplify immune response.18–
23

In other studies, aged subjects, both human and mice, exhibit reduced

expression of key inflammatory cytokines to acute insult in response to acute
injury.24–29 Dysfunctional aging-associated cellular inflammatory responses such
as this are characterized as “immunosenescence”.30–32
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Ab’s contribution to AD becomes more apparent when viewed through
aging and its associated changes in the immune response. Symptoms that
manifest in AD, including increased Ab production and aggregation, provoke
immune responses, such as microglial activation, persistent activation of the
inflammasome, production of inflammatory cytokines, etc., that indicate the
participation of immunity and inflammation in AD’s onset or advancement.33–35
Chronic neuroinflammation has emerged as an important factor in AD
etiology.16,17,36 However, both in vivo and in vitro studies that examined the effect
of various anti-inflammatory agents have offered mixed results attributed to
variability in the duration of exposure and degree of inflammation present.37 In
addition, there is increasing evidence that systemic immune challenges influence
and perhaps even drive Alzheimer’s pathology in ways we are only just beginning
to understand.38–42 To effectively identify novel potential therapeutics for AD, we
must begin our assessment with an in vitro model that allows us to evaluate
therapeutic candidates for their collective impact on factors that appear to
contribute to AD pathology, particularly the chronic or elevated-basal inflammatory
state found in aging.

1.3 The Receptor for Advanced Glycation End-products
The receptor for advanced glycation end-products, or RAGE, is a key
pattern recognition receptor of the innate immune response that may function as
a strategic target for AD, both for its inflammatory potential and its interaction with
Ab. RAGE is expressed on macrophages, microglia, and neurons at low basal
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levels, and pronounced upregulation of RAGE accompanies neuroinflammation
and AD as well as other inflammatory pathologies, such as diabetes. 43–45 Soluble
RAGE is constitutively expressed under normal conditions, and may function
through competitive inhibition as a component within an auto-regulatory
mechanism.45–47 It is through soluble RAGE generation that one link between
chronic inflammation, RAGE, and Ab can be found: a-secretase, the enzyme that
cleaves transmembrane RAGE to produce its soluble form is also responsible for
the cleavage of Ab’s parent molecule (APP) into its non-amyloidogenic (and
neurotrophic) form.45,48
The extracellular region of RAGE is comprised of three immunoglobulin-like
domains: one N-terminal variable (V) region, followed by two constant (C1 and C2)
regions separated by a flexible linker. The majority of extracellular binding occurs
at the V-C1 domain, with oligomeric and fibrillar Ab chiefly binding at the V region,
and other intermediate Ab aggregates recognizing various binding sites throughout
the V-C1 domain45,49 (Figure 1.1). Upon ligand-binding, transmembrane RAGE
can activate multiple signaling pathways to influence the magnitude and character
of the immune response, as well as initiate a positive feedback cycle that
upregulates its own transmembrane expression at the productive expense of its
soluble form.45,50,51

Both soluble and transmembrane RAGE expression

(Figure 1.2) can be viewed as either an anticipatory and compensatory mechanism
that depends primarily on the local environment and the specific type of cell
involved. In some circumstances, sustained RAGE activation and upregulation
promotes cellular survival, neuronal development, and repair, while in other
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settings RAGE triggers intrinsic apoptosis.44,52 Therefore, transmembrane and
soluble RAGE expression is altered as part of a feed-forward mechanism for
environmental stress or exposure and functions as a means through which cells
anticipate and interpret their local environment that may also serve as a source of
dysfunction in chronic inflammation.46,49,53–55
RAGE-mediated signaling appears to play a role in AD pathology and is
also relevant in the progression of diseases that represent an increased risk in AD,
such as Type II diabetes and cardiovascular disease.56,57 Ab is a ligand for RAGE,
and some evidence suggests that blocking specific binding domains on RAGE may
thwart some of Ab’s neurotoxic effects.58–60 In phase II clinical trials, patients that
received low doses of the small-molecule RAGE antagonist and potential AD
therapeutic Azeliragon demonstrate significantly improved outcomes one year
later, yet produced negative patient outcomes with high-dose administration.61
This evidence reinforces the concept that wholesale abolition of RAGE-associated
activity is undesirable, as this activation appears necessary for adaptation at the
cellular level.

1.4 Peptoids as Therapeutics for Neurodegeneration
In addition to the need for competent neurotherapeutics, neurodegenerative
illnesses such as AD also face challenges in the delivery across the blood brain
barrier of a potential therapeutic at an effective dosage.62,63 The challenge
presented by the blood brain barrier to large molecules has shifted focus to small
molecule or peptide therapeutics.64–70 Small molecules frequently lack specificity
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and may require frequent exposure or high concentrations to achieve the desired
result, and the benefit of these inhibitors is generally mitigated by the toxicity that
arises as a byproduct of treatment at these levels or frequency.71–73 These factors
may also introduce a level of variability, and thus complexity, that could make the
effective identification of a consistently effective therapeutic more difficult. 74,75
In contrast, peptide therapeutics may be synthesized to achieve desired
specificity.

Peptides

have

attracted

increased

attention

as

potential

neurotherapeutics attributed in part to a better understanding of the role of
protein-protein interactions and their functional relevance in neurological disease.
After the determination of the KLVFF hydrophobic core of Ab (residues 16 – 20)
as the key recognition sequence responsible for Ab aggregation,74,75 researchers
have used this sequence to produce peptide variants homologous to the KLVFF
hydrophobic core that bind to Ab and inhibit aggregation in vitro.

76–82

Unfortunately, the in vivo performance of these and other peptide therapeutics has
been limited by their vulnerability to proteases.83–90 Structural modifications to
increase the physiological half-life of various peptides have been employed to
circumvent this vulnerability. D-amino acid substitution was used to enhance
stability in an antimicrobial peptide, but the modification affected the interaction
between the peptide and its target, ultimately reducing therapeutic activity.88
Alterations such as terminal acetylation or amidation have also overcome
vulnerability to proteolysis, but at the expense of efficacy90–92 and the surrounding
physiological environment.90
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Peptoids, or oligomers of N-substituted glycines, are a unique class of
peptidomimetics that achieve the specificity of peptides, afford the mobility of small
molecule therapeutics, and are invulnerable to proteolysis.3 These desirable
attributes are conferred through a shift in side-chain placement from the a-carbon
to the amide nitrogen (Figure 1.3).3,93 Although this modification creates an achiral
backbone, the addition of chiral side chains and a stable polyproline type-1-like
helix with three monomers per turn induces helicity; inclusion of chiral and aromatic
side chains produces a helical pitch of ~6 Å, accordant with the characteristic
b-sheet spacing observed in the backbone of amyloid aggregates.

94–99

Their

invulnerability to proteases, as well as other attractive qualities such as diminished
immunogenicity, enhanced cellular permeability, and capacity for intranasal
administration make peptoids immensely attractive as neurotherapeutic agents.3
Our lab has previously evaluated variants of a rationally-designed peptoid mimic
of the KLVFF hydrophobic core of Ab for their ability to modulate Ab
aggregation.99,100
The

investigation

of

peptoids

as

potential

therapeutics

for

neurodegeneration is in its beginnings. Peptoids that inhibit Ab1-40 aggregation
have been discovered through rational design and the use of combinatorial
libraries,99–101 and peptoids have been used in the design of a diagnostic tool to
identify AD-specific antibodies. 102,103 In Huntington’s disease, a mouse model was
used to demonstrate a that peptoid specific for expanded polyglutamine proteins
inhibits the aggregation of Htt-N-53Q in vitro and demonstrates neuroprotective
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effects in vivo.104 While small molecule inhibitors have been investigated as
potential RAGE antagonists, peptoids have yet to be applied to this end.

1.5 Innovation
Prior development of AD therapies has primarily emphasized inhibition of
Ab production and/or aggregate formation; this focus has yielded limited success
in clinical trials.105,106 Inconsistency mars the success of in vivo and in vitro studies
that examine the effect of various anti-inflammatory agents, an outcome attributed
to the fluctuation in the inflammatory state across experimental models.37 The
aforementioned hallmarks of AD, including increased Ab production and
aggregation, provoke immune responses such as microglial activation, persistent
activation of the inflammasome, production of inflammatory cytokines, etc.,
indicating that immunity plays some role in AD’s onset or advancement.33–35 Aging
manifests as chronic low-level systemic inflammation in the absence of infection,
referred to as “inflammaging”. This pro-inflammatory phenotype evolves over time
and with chronic exposure to molecular stress and contributes to the evolution of
many age-related illnesses, including AD.16,17 However, many in vitro studies that
evaluate potential Ab-related therapies assess the acute response of otherwise
healthy cells.
Our lab has previously studied Ab aggregation, as well as cellular response
to acute Ab exposure; we have also examined potential therapeutics such as
polyphenols and other peptoid inhibitors for their abilities to abrogate the formation
of the more toxic aggregates of both forms of Ab.100,107–111 Expanding our focus to
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include aspects of the chronic inflammatory response will uncover alternate
strategies and lead to novel approaches in AD treatment. Because the
microenvironment of the brain is chiefly maintained through microglia, the resident
macrophage of the brain, macrophages will be employed to observe these
responses.36,112
More recent research indicates that systemic immune challenges influence
and perhaps even drive Alzheimer’s pathology in ways we are only just beginning
to understand.38–42 To effectively study AD, we must mimic to some degree the
cellular inflammatory environment that accompanies aging. Rather than using
acute exposure alone, this in vitro model examines the response of immune cells
conditioned with chronic exposure to low concentrations of pro-inflammatory
stimuli. Alterations in RAGE expression are correlated with concurrent changes in
cytokine expression indicative of macrophage polarization and inflammatory state.
In addition, this model is used to assess an achiral peptoid mimic of the Ab KLVFF
hydrophobic core, JPT1a, as a prospective therapeutic for AD. JPT1a was
designed by Dr. Shannon Servoss (University of Arkansas)99 (Figure 1.4), and
previous research has demonstrated JPT1a’s capacity to reduce the total number
of Ab1-40 aggregates formed, as well as alter the morphology of said aggregates.99
JPT1a maintains the side-chain chemistry of its chiral analogue, JPT1, but
achieves its achiral form through the replacement of JPT1’s chiral side chains with
side chains that lack a methyl group at the a-carbon position.99 This study chiefly
examines this achiral peptoid mimic for its ability to modulate transmembrane
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RAGE expression and pro-inflammatory cytokine production in the presence of a
chronic pro-inflammatory stimulus.

1.6 Study Overview
This research first develops an in vitro cellular model that utilizes RAGE
expression

and

the

concurrent

inflammatory

response

to

simulate

immunosenescence, the dysfunctional cellular inflammatory response associated
with aging. Mimicry of key aspects of immunosenescence, such as abnormal
cytokine response to inflammatory stimuli and controlled upregulation of
transmembrane RAGE, are achieved; use of this model facilitates exploration of
potential therapeutics within the context of chronic and age-associated
inflammation.
Next, this model is applied to the investigation of JPT1a and its chiral
analogue to explore their impact on transmembrane RAGE expression and
inflammatory cytokine response in the presence of chronic inflammatory stimuli.
Finally, this study seeks to characterize the interaction between this achiral peptoid
and RAGE. These studies comprise the three aims of this research and are
summarized below.

1.6.1 Develop and implement an in vitro cellular model to simulate key aspects of
immunosenescence
Many in vitro cellular studies that evaluate potential AD therapeutics assess
the acute response of otherwise healthy cells. To effectively identify novel potential
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therapeutics for AD, we must begin our assessment with an in vitro model that
allows us to evaluate therapeutic candidates for their collective impact on factors
that appear to contribute to AD pathology, particularly the chronic or elevated-basal
inflammatory state found in aging. This model was developed on the hypothesis
that chronic low-dose inflammatory stimulation of human THP-1 macrophages will
achieve a state that mimics key attributes found in immunosenescent cells, such
as elevated levels of transmembrane RAGE expression and co-incident changes
in the cellular response, as well as aberrant response to acute inflammatory insult.
The influence of cytokine buildup on this effect was assessed through a daily
volume exchange, in which a portion of the supernatant is replaced daily to
attenuate cytokine buildup while maintaining the concentration of inflammatory
stimulus present. Transmembrane RAGE expression relative to the surface area
occupied by the cell was evaluated via immunocytochemistry, and inflammatory
cytokine expression was assessed via colorimetric enzyme-linked immunosorbent
assay (ELISA).

1.6.2 JPT1a modulates RAGE expression and chronic inflammation in THP1
macrophages
Using the model developed in the first aim, this aim tests the hypothesis
that JTP1a, a peptoid inhibitor of Ab aggregation, modulates transmembrane
RAGE expression and the concurrent cellular inflammatory cytokine response in
the presence of a chronic low-level pro-inflammatory stimulus. JPT1a is also
assessed for its ability to reverse transmembrane RAGE expression in
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previously-stimulated macrophages and halt inflammatory cytokine production. To
examine the relevance of molecular structure, JPT1, the chiral analogue for JPT1a,
is also evaluated for the capacity to attenuate transmembrane RAGE expression
and inflammatory cytokine response in the presence of a chronic low-level
pro-inflammatory stimulus.

1.6.3 JPT1a binds to RAGE selectively
Here, the hypothesis that RAGE binds selectively and with high affinity to
JPT1a is tested using a modified colorimetric ELISA. Selectivity is assessed by
comparing the binding of JPT1a with RAGE to that of JPT1a with E-cadherin, a
cell-adhesion molecule expressed on macrophages. Binding affinity is next
determined colorimetrically via modified ELISA from samples of JTP1a and RAGE
that reach binding equilibrium in solution. JPT1a appears to have a low-nanomolar
affinity for RAGE.
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Figure 1.1. Binding domains of RAGE.41 The extracellular region of RAGE is
comprised of three immunoglobulin like domains: one N terminal variable (V)
region, followed by two constant (C1 and C2) regions separated by a flexible linker.
The majority of extracellular binding occurs at the V C1 domain, with oligomeric
and fibrillar Ab chiefly binding at the V region, and intermediate Ab aggregates
recognizing various binding sites throughout the V C1 domain.

14

Figure 1.2. RAGE and its splice variants.49 Soluble RAGE is constitutively
expressed under normal conditions and may function as a component within an
auto-regulatory mechanism through competitive inhibition. It is through soluble
RAGE generation that one link between chronic inflammation, RAGE, and Ab can
be found: a-secretase, the enzyme that cleaves transmembrane RAGE to produce
its soluble form, is also responsible for the cleavage of Ab’s parent molecule (APP)
into its non-amyloidogenic (and neurotrophic) form.
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(a)

(b)

Figure 1.3. Peptide versus peptoid. While their backbones are similar, the side
chains are attached to the a-carbon in peptides (a), while peptoids have side
chains attached to the amide-nitrogen (b). This modification confers resistance to
proteolytic degradation.
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Figure 1.4. Structure of peptoid JPT1a.99 An achiral peptoid mimic of the Ab
KLVFF hydrophobic core (residues 16 – 20), JPT1a, was designed by Dr.
Shannon Servoss (University of Arkansas) as a potential peptoid therapeutic for
AD.
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CHAPTER 2:
MATERIALS AND METHODS

2.1 Materials
Phorbol 12-myristate 13-acetate (PMA), bovine serum albumin (BSA), and
Triton X-100 were purchased from Sigma-Aldrich (St. Louis, MO) and stored
at -20°C and 4°C, respectively. Dimethyl sulfoxide (DMSO) was purchased from
EMD Biosciences (San Diego, CA). Lipopolysaccharide (LPS), Tween-20, and
paraformaldehyde 4% (PFA) in phosphate-buffered saline (PBS), black-walled
96-well plates, and clear flat-bottomed MaxiSorp™ 96-well plates were obtained
from VWR (Radnor, PA). Monoclonal RAGE antibody (A-9) was purchased from
Santa Cruz Biotechnology (Dallas, TX). Normal donkey serum (NDS) was acquired
from Jackson ImmunoResearch (West Grove, PA), Phalloidin-iFluor 488 reagent
was acquired from Abcam (Cambridge, MA), and Alexa Fluor™ 555 secondary
antibody was obtained from Thermo Fisher Scientific (Waltham, MA). A 2,3-Bis-(2Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide (XTT) kit was
purchased from American Type Culture Collection (Rockville, MD). Coating buffer,
TMB substrate, and cytokine ELISA MAX™ kits for IL-1b, IL-6, IL-8, IL-10,
GM-CSF, and TNF-a were purchased from BioLegend (San Diego, CA). Soluble
human RAGE and modified ELISA components for RAGE selectivity assays were
purchased from Aviscera Bioscience, Inc. (Santa Clara, CA). Human E-cadherin
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was purchased from Sino Biological (Wayne, PA), and a human E-cadherin
Quantikine ELISA kit was purchased from R&D Systems, Inc. (Minneapolis, MN).

2.2 Media and cell lines
Human pre-monocytic cell line THP-1 cells from American Type Culture
Collection (Rockville, MD) were maintained in RPMI 1640 medium (American Type
Culture Collection formulation).

Antibiotics were added to achieve a final

concentration of 100 units/mL penicillin and 100 µg/mL streptomycin; medium was
supplemented with 10% FBS. Cell cultures were maintained at 37°C in a humid
atmosphere of 5%/CO2/95% air.

2.3 Differentiation of THP-1 monocytes
Proliferative, non-adherent THP-1 monocytes were differentiated into
adherent, non-proliferative macrophages via application of PMA as prescribed by
Daigneault et al.113 to achieve behavior and phenotype that closely resembles that
of primary human monocyte-derived macrophages. PMA was first solubilized in
DMSO to a concentration of 1 mM, aliquotted and stored at -20°C until needed.
THP-1 monocytes were seeded onto 22 x 22 mm glass coverslips in a 6-well tissue
culture plate using RPMI 1640 medium supplemented with 200 nM PMA to
achieve a final density of 2.25 x 105 cells/mL. Differentiation medium was removed
after 3 days (at the time of experiment).
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2.4 Determination of cellular transmembrane RAGE expression
Cells were briefly rinsed with RPMI 1640 medium supplemented with 1%
FBS before fixation with PFA. Fixed macrophages were subsequently rinsed with
sterile PBS, blocked with 5% BSA/DPBS and 5% normal donkey serum prior to
treatment with primary RAGE antibody overnight at 4°C. The following day, cells
were rinsed three times with 1% BSA/PBS and blocked with 5% normal donkey
serum and then treated with Alexa Fluor 555 secondary antibody for 2 h at 25°C.
After

removal

of

secondary

antibody,

cells

were

permeabilized

with

0.1% Triton X-100/0.01 M glycine in PBS for 8 min, then rinsed three times with
1% BSA/DPBS and once with sterile DPBS.

Phalloidin-iFluor 488 reagent

(1:3000) was applied to cells overnight at 4°C for visualization of the cytoskeleton;
coverslips were mounted with DAPI to facilitate visualization of nuclei.
Two-slice multichannel z-stacks of stained samples were imaged with a
Zeiss LSM 510 META Confocal Scanning Laser Microscope using a plan-neofluar
40X/1.3 oil DIC immersion objective (Carl Zeiss); three of these multi-channel
images were obtained from each slide in each experiment. All multi-channel
images were converted to TIFF file format via ImageJ64 software114,115 for
quantitative image analysis using a custom subroutine written in Matlab™ software
[Appendix A]. Acquisition settings unique to each experiment require normalization
within each experiment to allow comparison across all trials; results are reported
as fraction of the positive or negative control.
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2.5 Cytokine analysis of cellular supernatant via ELISA
On the day prior to each ELISA, 96-well plates (included with ELISA kits)
were coated with capture antibody per kit instructions and incubated overnight at
4°C. The following day, the coating buffer containing capture antibody was
removed, and each well washed three times with wash buffer (PBS with 0.05%
Tween-20) and blocked with kit-included buffer. Cellular supernatants collected
during experimentation were thawed to room temperature. Previous protocol
refinement determined the optimal dilution factor of supernatant for assessment of
each cytokine (Table 2.1); samples were diluted in this manner with assay diluent
included in each kit respective to its cytokine and applied to antibody-coated wells
for 2 h.
After sample removal, plates were washed three times with wash buffer and
treated with kit-included detection antibody. After 1 h, the detection antibody was
removed from each plate, and plates were washed once again. Dilute Avidin HRP
was applied to each plate, incubated for 30 min, and washed four times with wash
buffer. Substrate solution relevant to each kit was applied to each plate for 1 to
2 minutes, and the color reaction was halted with an acidic stop solution containing
2N H2SO4. Color intensity at 450 nm and 570 nm was measured via
spectrophotometry on a SpectraMax microplate reader (Molecular Devices,
San Jose, CA), and a standard curve was determined in parallel for each plate as
directed per kit instructions. Results for all cytokines are normalized to the positive
control within each experiment.
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2.6 XTT reduction assay to determine peptoid toxicity
Peptoid toxicity was assessed via XTT cell proliferation assay. Tetrazolium
dye, or XTT, is a colorless or near-colorless yellow reagent. Upon treatment with
XTT, metabolically-active cells reduce XTT to form a brightly-colored and
water-soluble formazan derivative. N-methyl dibenzopyrazine methyl sulfate
(PMS) facilitates this process, as inclusion of PMS promotes uptake of XTT by
treated cells.116–119 THP-1 monocytes were cultured as described in Section 2.2,
seeded into a black-walled 96-well plate to a concentration of 2.25 cells/mL, and
differentiated into macrophages as described in Section 2.3. After 3 days, the
differentiation medium was removed and macrophages were treated with medium
supplemented with RPMI-1640 medium supplemented with 1% FBS and JPT1a at
concentrations of 50, 25, 10, 5, and 1 µM for 3 days. On the third day of exposure,
an XTT assay kit from American Type Cell Culture (Rockville, MD) was used to
assess XTT reduction in treated cells. Per kit instructions, XTT Reagent and
Activation Reagent were warmed to 37°C and swirled gently until solutions were
clear in appearance. Activation Reagent was diluted 1:50 into XTT Reagent, and
50 µL of this mixture was added to each well. The plate was incubated at 37°C in
a humid atmosphere of 5% CO2/95% air, and removed for colorimetric assessment
at 2, 4, and 24 h. Per kit instructions, absorbance values at 450 nm and 630 nm
were obtained at these time intervals via SpectraMax microplate reader (Molecular
Devices, San Jose, CA). Viability was reported as fraction of cells treated with the
vehicle (DMSO) alone.
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Table 2.1 Dilution table for supernatant collected from THP-1 macrophages.

Cytokine

Dilution
factor

IL-1β
IL-6
IL-8
IL-10
GM-CSF
TNF-α

1:5
1:2
1:20
--1:4
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CHAPTER 3:
DEVELOPMENT OF AN IN VITRO CELLULAR MODEL
TO MIMIC THE EFFECTS OF CHRONIC INFLAMMATION

3.1 Introduction
To effectively identify novel potential therapeutics for AD, we must use an
in vitro model that allows us to evaluate therapeutic candidates for their collective
impact

on

factors

relevant

aggregation/oligomerization,

to

chronic

AD

pathology,

inflammation,

including
and

Ab
RAGE

expression.50,57,61,120–122 Recent studies with RAGE have shown that both
membrane-bound and soluble RAGE expression is altered as part of a
feed-forward mechanism for environmental stress or exposure; therefore, RAGE
is a means through which cells anticipate and interpret their local environment, and
RAGE may also be a source of dysfunction in chronic inflammation.49,53 RAGE was
chosen as one of the key facets of this model because of its increasing relevance
in studies of aging, inflammation, and neurological disorders.123–127
Activation of RAGE upon ligand-binding appears to be dose-, time-, and
context-dependent and may precipitate multiple outcomes [Section 1.3]. Because
activation of RAGE may initiate multiple signaling pathways that may or may not
precipitate unresolved inflammation,43,49,120 inflammatory cytokine response must
also be evaluated in concert with transmembrane RAGE expression [Section 1.2].
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This chapter describes the development of an in vitro cellular model that uses
THP-1 macrophages to mimic key aspects of chronic inflammation and
immunosenescence through upregulation of transmembrane RAGE expression
and altered cytokine response to acute inflammatory stimulus.

3.2 Materials and Methods
3.2.1 Differentiation of THP-1 monocytes
THP-1 monocytes were cultured and differentiated as described in
Section 2.3.

3.2.2 Chronic conditioning of macrophages, daily volume exchange, and acute
treatment
Upon differentiation, macrophages received medium supplemented with
1% FBS alone or medium containing low-dose (2 ng/mL) LPS as a chronic
pro-inflammatory stimulus for 3 days. This concentration of LPS was calculated as
~15% of the equivalent dose required to induce septic shock in the average
adult.128 To examine the effect of cellular products on cellular response, 50% or
25% of the total medium volume per well (2 mL) was replaced daily with untreated
media (control) or media containing 2 ng/mL LPS; this process is described
hereafter as the daily volume exchange, or DVE.
After 3 days of chronic exposure, cells received medium supplemented with
1% FBS alone or acute treatment with medium containing a high dose of LPS
(10 ng/mL) for a brief 4-hour interval. Cellular supernatant was harvested before
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and after acute exposure, and these samples were immediately centrifuged at
1200 rpm for 10 min at 25°C to remove any cells or debris. The top 80% of this
volume was subsequently removed and stored at -80°C for later assessment of
cytokine expression via ELISA.
Framework for evaluation was comprised of 4 scenarios: cells that remained
untreated for both the chronic and acute phases of the experiment
(Untreated/Untreated), cells that remained untreated for the chronic phase of the
experiment but received acute exposure to a high-dose proinflammatory stimulus
(Untreated/LPS), cells that received chronic conditioning with the low-dose
proinflammatory but remained untreated for the acute phase (LPS/Untreated), and
cells that were chronically conditioned with the low-dose proinflammatory stimulus
as well as acute exposure to the high-dose proinflammatory stimulus (LPS/LPS).

3.2.3 Preparation of treated cells for analysis of transmembrane RAGE expression
After supernatant removal post-acute exposure, cells assessed for RAGE
expression using immunocytochemistry as described in Section 2.4. Results were
normalized within each experiment to cells which remained untreated for both the
chronic and acute phases of experimentation (i.e. the negative control).

3.2.4 Analysis of cellular supernatant for inflammatory cytokine expression
Cellular supernatant was harvested before and after acute exposure for
cytokine testing and immediately centrifuged at 1200 rpm for 10 min at 25°C to
isolate supernatant free from any cellular debris. Processed supernatant was
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stored at -80°C. ELISAs were performed as described in Section 2.5 for the
analysis of inflammatory cytokines IL-1b, IL-6, IL-8, IL-10, GM-CSF, and TNF-a.
Results for all raw sample data within each experiment are obtained as
concentrations in ng/mL. Results are reported as fraction of the positive control.

3.2.5 Statistical Analysis
GraphPad Prism 8.0 software was used to analyze data generated from
images for transmembrane RAGE expression within each DVE subset via one-way
ANOVA with Tukey’s post-hoc analysis. Generated data for each cytokine was
analyzed for statistical significance via one-way ANOVA within each DVE subset
with Dunnett’s post-hoc analysis using GraphPad Prism 8.0 software. p < 0.05 was
considered significant.

3.3 Results
3.3.1 Upregulation of transmembrane RAGE is dependent upon the DVE
To evaluate the impact of cellular product on cellular response and changes
in the basal inflammatory state, 50% or 25% of the total medium volume/well was
replaced daily for differentiated macrophages maintained with a treatment of
0 ng/mL (control) or a chronic low-dose (2 ng/mL) of LPS. The requirement of the
persistent presence of a RAGE ligand for transmembrane RAGE upregulation to
occur is confirmed in Figures 3.1 B and D, as only macrophages which received
chronic exposure to the low-dose proinflammatory stimulus exhibit notable
transmembrane RAGE expression in each DVE subset. In contrast, the response
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of these conditioned cells to acute insult (10 ng/mL LPS) varies with the DVE. For
the 50% DVE subset, chronically conditioned macrophages that receive the acute
stimulus display a further increase in transmembrane RAGE expression,
evidenced by the higher expression of RAGE in cells that received LPS in both the
chronic and acute phases relative to those that were treated with LPS in the chronic
phase alone (Figure 3.1 B) In contrast, cells that suffered both chronic and acute
insult in the 25% DVE subset exhibit a significant decrease in transmembrane
RAGE expression relative to those treated in the chronic phase alone
(Figure 3.1 D)

3.3.2 Cytokine analysis post-chronic exposure
As shown in Figure 3.2 shows cytokine production resultant from chronic
treatment alone led to cytokine buildup for all cytokines (IL-1b, IL-6, IL-8, IL-10,
TNF-a, and to a lesser extent, GM-CSF) within the local cellular environment.
Although the comparison of the positive controls for the 50% and 25% DVE
subsets is not demonstrated in the figure, the results were as expected: the
concentration of cytokines was altogether lower for the 50% DVE subset as
compared with the 25% DVE subset. The average concentration of IL-10 and IL-8
in the 50% DVE subset was approximately 25% less than that in the 25% DVE
subset upon cessation of chronic conditioning. Similarly, the concentrations of
TNF-a and IL-6 in in cells that received 50% DVE were approximately half that of
those which received 25% DVE, and the concentrations of GM-CSF and IL-1b in
the 50% DVE set were 65% less than the 25% DVE set.
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3.3.3 Cytokine analysis post-acute exposure
To evaluate how chronic conditioning affects cellular response to acute
stimuli, chronically stimulated cells were exposed to an acute treatment of high
concentration

proinflammatory

stimulus.

As

shown

in

Figure

3.3,

chronically-conditioned cells exposed to the acute stimulus exhibit a pronounced
reduction in cytokine expression of IL-1b, IL-6, and TNF-a relative to cells that
received only an acute stimulus, demonstrating the significant effect of chronic
inflammatory conditioning on response to acute inflammatory stimulus. IL-10
demonstrates a similar trend, although this effect is intermediate; there is no
significant effect or reduction in cytokine response for IL-8, IL-10, and GM-CSF.

3.4 Discussion
Immunosenescence, or the dysfunctional cellular inflammatory response
associated with aging, is characterized in part by abnormal response to
inflammatory stimuli as well as an overall systemic increase in the basal
inflammatory state.16,30,31,129–131 The objective of this in vitro model is to mimic the
phenomenon of immunosenescence; this objective is achieved in several ways.
First, the model achieves the controlled upregulation of transmembrane RAGE
expression in vitro (Figure 3.1); physiological upregulation of transmembrane
RAGE expression (in all organs but the skin and lungs) requires the accumulation
or persistent presence of its ligands,43,49,120 and impaired clearance and/or the
build-up of potential ligands and/or toxic metabolites appears to be a significant
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contributor to neurodegenerative disease.15,132–135 This model also demonstrates
altered RAGE expression relative to the accumulation of cellular products, with an
apparent downregulation in RAGE expression in conditioned cells within the 25%
DVE subset further exposed to an acute stimulus. This result may indicate cellular
dysfunction or overstimulation secondary to the conditioning and buildup within the
local microenvironment.
This model also achieves simulation of immunosenescence through
cytokine expression. Age-related inflammation, or inflamm-aging, presents as
higher levels of both pro− and anti-inflammatory markers to suggest an overall
increase in activation that may or may not be accompanied by an inflammatory
insult (such as illness or injury).16,30,31,129–131,136 In other studies, aged subjects
(human and mice) display diminished IL-6 and TNF-a expression in response to
acute insult.24–29 This model effectively demonstrates this phenomenon for three
cytokines (Figure 3.3). The IL-6 response to acute insult was significantly lower in
the pre-conditioned cells of both DVE subsets (p < 0.0001 in the 50% DVE subset,
and p < 0.001 in the 25% DVE subset) relative to the previously untreated cells.
Expression of IL-1b and TNF-a to acute insult in pre-conditioned cells was similarly
lower (p < 0.0001 in both DVE subsets). Interestingly, this trend of diminished
response in pre-conditioned cells also applied to the IL-10 response, although the
results did not achieve significance in the 25% DVE subset.
In summary, AD is an aging-related illness, yet our lab and many others
have previously evaluated inhibitors within the context of acute response. To
effectively study potential AD therapeutics, we must use an in vitro cellular model
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that mimics to some degree the cellular inflammatory environment that
accompanies aging. The cellular model proposed in this study facilitates
therapeutic exploration through its mimicry of key aspects of immunosenescence.
RAGE-ligand interaction sustains and amplifies the immune response; through its
focus on transmembrane RAGE expression, this model offers a gateway to
modulate aging-associated inflammation. These data support this framework, as
the use of the DVE best recapitulates local inflammatory cytokine buildup that
accompanies aging-associated inflammation and precipitates cellular dysfunction.
Examination of potential therapeutics within this context will provide greater
support for their legitimate efficacy.
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Figure 3.1. Upregulation of transmembrane RAGE. THP-1 macrophages were
treated with 0 ng/mL (control) or 2 ng/mL LPS for 3 days with DVE equivalent to
50% (A,B) or 25% (C and D) of the total volume. On day 3, macrophages were
exposed to 0 ng/mL (☐) or 10ng/mL LPS (■) for 4 h prior to fixation and staining
for RAGE (A and C), followed by staining specific for the cytoskeleton and nuclei
of the cells (not shown). Slides were imaged via confocal microscopy and analyzed
via custom Matlab™ subroutine to determine the average quantity of RAGE per
volume of cell. Results are normalized to wholly untreated cells within each 50%
DVE and 25% DVE subset, averaged, and assessed via one-way ANOVA. Error
bars indicate SEM, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001 vs control; †p < 0.05.
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Figure 3.2. Inflammatory cytokine expression in the chronic phase. THP-1
macrophages remained untreated or were treated with 2 ng/mL LPS for 3 days,
with DVE equivalent to 50% (☐) or 25% (■) of their total volume while maintaining
a constant dose of chronic LPS dose. On day 3, supernatant was harvested and
analyzed via ELISA for expression of inflammatory cytokines IL-1b, IL-6, IL-8,
IL-10, GM-CSF, and TNF-a relative to the positive control (as indicated by the
dashed line). A one-way ANOVA was used to analyze cytokine response within
each subset. Error bars indicate SEM, n = 3 – 5. ****p < 0.0001 vs the positive
control.
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Figure 3.3. Chronic conditioning affects acute response of inflammatory
cytokines. THP-1 macrophages remained untreated or were treated with 2 ng/mL
LPS for 3 days, with daily volume exchange equivalent to (☐)50% or (■) 25% of
their total volume while maintaining a constant chronic low dose of LPS (2ng/mL).
Following chronic conditioning, the cells were immediately subjected to 4-hour
treatment with 10 ng/mL of LPS to simulate an acute inflammatory insult.
Supernatant from this acute treatment was harvested from the cells and analyzed
via ELISA for the expression of cytokines IL-1b, IL-6, IL-8, IL-10, GM-CSF, and
TNF-a. The cytokine expression observed post- acute treatment is reported here;
results are labeled as chronic/acute. The results for each combination of cell
treatment were normalized to cells that remained untreated for the chronic phase
of the experiment but received the acute LPS treatment (UT/LPS), i.e. the positive
control for the acute phase of the experiment within each DVE subset, indicated
by the dashed line at 1.0. Significance relative to the positive control shown as:
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Error bars indicate SEM,
n = 3 – 5.
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CHAPTER 4:
THE EFFECT OF JPT1A ON RAGE EXPRESSION AND THE INFLAMMATORY RESPONSE:
A POTENTIAL THERAPEUTIC FOR ALZHEIMER’S DISEASE

4.1 Introduction
Peptides have attracted increased attention as potential neurotherapeutics
attributed in part to a better understanding of the role of protein-protein interactions
and their functional relevance in neurological disease; however, the in vivo
performance of peptide therapeutics has been limited by their vulnerability to
proteases.83–90

Peptoids,

or

oligomers

of

N-substituted

glycines,

are

peptidomimetics that circumvent this vulnerability through repositioning of the
side-chain from the a-carbon to the amide nitrogen.3,93 Their invulnerability to
proteases, as well as other attractive qualities such as diminished immunogenicity,
enhanced cellular permeability, and capacity for intranasal administration, make
peptoids immensely attractive as neurotherapeutic agents.3
A peptoid mimic of the Ab KLVFF hydrophobic core (residues 16 – 20),
JPT1a, was designed by Dr. Shannon Servoss (University of Arkansas) as a
potential peptoid therapeutic for AD (Figure 4.1 A). While its chiral analogue, JPT1,
contains chiral aromatic and aliphatic side chains that induce a helical secondary
structure in methanol and water (Figure 4.1 B), JPT1a maintains its side chain
chemistry while achieving achirality through replacement of its chiral side chains
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with achiral forms.99 The ~6Å spacing between adjacent aromatic side chains is
congruent to the b-sheet backbone spacing observed in Ab aggregates. Previous
research with JPT1a has established its capacity to modulate Ab1-40 aggregation,
as well as alter the morphology of the Ab1-40 aggregates formed.99 Here, we use
the previously-described in vitro model to evaluate the impact of JPT1a on RAGE
expression and the concurrent inflammatory cytokine response induced by chronic
exposure to a low-level proinflammatory stimulus, LPS. Next, we examine the
ability of JPT1a to reverse transmembrane RAGE expression and attenuate the
associated inflammatory cytokine expression previously induced through chronic
exposure to a low-level proinflammatory stimulus, LPS. Finally, the relevance of
chirality to therapeutic efficacy is explored via comparison JPT1’s capacity to
modulate transmembrane RAGE expression and inflammatory cytokine response.

4.2 Materials and Methods
4.2.1 Differentiation of THP-1 monocytes
THP-1 monocytes were cultured and differentiated as described in
Section 2.3.

4.2.2 Examination of peptoid inhibitors within a cell model of chronic inflammation
JPT1a or JPT1 was solubilized in DMSO to achieve 10 mM concentration,
then diluted to a cell treatment of 50, 10, or 2 µM JPT1a with medium containing
1% FBS alone (control) or a chronic low-dose of 2 ng/mL LPS. The DVE
component previously used in Chapter 3 was discontinued for these experiments,
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both to maximize cellular product buildup and to reduce the total amount of peptoid
used with each experiment. On day 3 of treatment, the cellular supernatant was
harvested from each sample and processed for cytokine analysis [Section 2.4],
which was performed via ELISA as described in Section 2.5. Macrophages were
then fixed and stained for RAGE, phalloidin, and DAPI as described in Section 2.4.
Slides were imaged via confocal microscopy and quantitative image analysis was
performed using a custom subroutine in Matlab™ as described in Section 2.4..

4.2.3 Examination of peptoid ability to reverse effects of chronic inflammation
JPT1a was evaluated for its ability to reverse or halt transmembrane RAGE
expression and attenuate the associated inflammatory cytokine response in THP-1
machrophages. Cells received treatment medium alone (control) or a chronic
low-dose of LPS (2 ng/mL) for 48 h. Following chronic treatment, half of the
supernatant was removed from each sample. JPT1a was added to the removed
treatment to achieve final concentrations of 25, 5, 1, or 0 µM JPT1a (positive
control), and the treatment was returned to the cells. The experiment was halted
after an additional 24 h, and supernatant was harvested [Section 2.4] for later
cytokine analysis via ELISA [Section 2.5]. Cells were fixed and stained for RAGE,
phalloidin, and DAPI [Section 2.4]. Slides were imaged via confocal microscopy,
and quantitative image analysis was performed using a custom subroutine in
Matlab™ [Section 2.4].
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4.2.4 Assessment of toxicity of JPT1a via XTT reduction assay
An XTT cell proliferation assay was used to determine the toxicity of JPT1a
at concentrations of 50, 25, 10, 5, and 1 µM for 3 days as outlined in Section 2.6.
Results are reported as fraction of the control.

4.2.5 Statistical Analysis
All generated data was analyzed for statistical significance via one-way
ANOVA with Dunnett’s post-hoc analysis using GraphPad Prism 8.0 software.
p < 0.05 was considered significant.

4.3 Results
4.3.1 JPT1a is capable of RAGE inhibition independent of Ab stimulation
The ability of JPT1a to prevent the upregulation of transmembrane RAGE
and inflammatory cytokine response in the presence of a chronic, low-dose
proinflammatory stimulus was examined. Figure 4.2 shows that cells treated with
a chronic, low-dose (2 ng/mL) of the proinflammatory stimulus LPS (positive
control) demonstrate a significant difference in transmembrane RAGE expression
relative to untreated cells (control) (p < 0.01). Co-incubation of the peptoid JPT1a
with the chronic proinflammatory stimulus attenuates transmembrane RAGE
upregulation. A dose-dependence of this response is observed, albeit significant
reduction is only observed at 50 µM JPT1a (p < 0.01). Also noteworthy is the lack
of RAGE upregulation observed with treatment of JPT1a alone, indicating that the
peptoid in itself does not function as a RAGE agonist.
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4.3.2

JPT1a inhibits inflammatory cytokine response independent of Ab

stimulation
Supernatant harvested from macrophages treated with a chronic, low-dose
(2 ng/mL) of the proinflammatory stimulus LPS (positive control) exhibit
significantly higher expression of inflammatory cytokines IL-1b, IL-6, and IL-8
relative to cells treated with the vehicle alone.(p < 0.001, p < 0.0001)
Co-incubation

of

JPT1a

with

chronic

low-dose

LPS

demonstrates

a

dose-dependent trend of attenuation for all three of these cytokines (Figure 4.3).
Treatment with 50 µM JPT1a significantly reduced LPS-stimulated production of
all three cytokines relative to the control (p < 0.001 for IL-1b, p < 0.0001 for IL-6
and IL-8), and treatment with the peptoid at 10 µM also produced a significantly
diminished response for IL-6 production (p < 0.01). These results correlate with
the trends observed in RAGE expression shown in Figure 4.2. Macrophages
treated with the peptoid alone displayed pro-inflammatory cytokine expression
similar to that of the vehicle, indicating that JPT1a does not induce an inflammatory
response.

4.3.3 JPT1a reverses RAGE expression in previously-stimulated macrophages
We next examined the capacity of JPT1a to reverse RAGE expression and
modulate the concurrent inflammatory cytokine response in previously-stimulated
cells.A significant difference (p < 0.001) in transmembrane RAGE expression is
observed in untreated macrophages versus those stimulated with a chronic
low-dose (2 ng/mL) of LPS (positive control). (Figure 4.4) JPT1a at 25 and 5 µM

39

significantly reduces RAGE expression in previously-stimulated macrophages.
Although reductions at 25 and 5 µM JPT1a achieve significance, it is of note that
these results do not mirror the dose-response relationship observed in
macrophages

that

received

JTP1a

and

the

proinflammatory

stimulus

simultaneously. The absence of this phenomenon may indicate a therapeutic
range of JPT1a in this context.
Supernatant harvested from previously-conditioned cells subsequently
treated with JPT1a revealed that application of JPT1a to previously-stimulated
cells has no significant effect on the expression of IL-1b, IL-6, or IL-8.

4.3.4 JPT1 inhibits transmembrane RAGE expression in a manner similar to JPT1a
The chiral analogue of JPT1a, JPT1, was introduced into the cellular model
to assess the impact of chirality on the performance of the peptoid as an inhibitor
of chronic inflammation and transmembrane RAGE expression. Again,
transmembrane RAGE was upregulated in macrophages following treatment with
chronic, low-dose (2 ng/mL) LPS, and JPT1 exhibits the capacity to modulate this
upregulation in a manner that is dose-dependent and similar in magnitude to that
observed with JPT1a.(Figure 4.6) Treatment with JPT1 alone is unprovocative of
transmembrane RAGE expression.
Figure 4.7 shows that the ability of JPT1 to modulate production of
proinflammatory cytokines follows a similar trend of dose-dependence as that
detected with JPT1a but is not as conspicuous, as treatment with 50 µM JPT1
significantly reduces IL-6 alone. Although this effect at 50 µM JPT1 fails to reach
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significance for IL-1b, a pronounced reduction is noted. Macrophages treated with
the peptoid alone demonstrate display no significant difference in expression of
pro-inflammatory cytokines relative to the control (VEH), indicating that JPT1 does
not induce an inflammatory response.

4.3.5 JPT1a is non-toxic to THP-1 macrophages
An XTT cell proliferation assay was used to assess the toxicity of JPT1a for
THP-1 macrophages. When macrophages were incubated with JPT1a at
concentrations of 50, 25, 10, 5, and 1 µM for 3 days, no discernible difference in
the metabolic activity of cells was observed (Figure 4.8). These results
demonstrate that JPT1a does not elicit an adverse toxic reaction.

4.4 Discussion
Alzheimer’s disease (AD) is a prevalent amyloidosis that currently lacks an
effective preventative treatment or cure, and the dramatic increase in our aging
population has greatly expanded the need for competent neurotherapeutics.1
Direct delivery of a potential therapeutic at an effective dose to a neurological
target is challenged by physiological barriers to efficacy such as proteolytic
vulnerability and the blood-brain barrier.62,63 The obstacle presented by the
blood-brain barrier has shifted strategies in therapeutic development to small
molecules and peptide therapeutics. Many of these compounds modulate Ab
aggregation kinetics or aggregate morphology or subvert the aggregation pathway
in some manner.64–70 Small molecules usually require frequent exposure or high
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concentrations to achieve the desired outcome, and the benefit achieved by these
inhibitors is generally mitigated by toxicity associated with treatment at these levels
and frequency.71–73 In addition, small molecule interaction with Ab can vary greatly,
complicating the identification of a potential therapeutic candidate.74,75 Thus, small
molecule therapeutics are problematic solutions for neurodegenerative illnesses
such as AD.
Peptides and peptidomimetics, however, can be synthesized to achieve
the desired specificity yet fall short of ideality in their proteolytic vulnerability.3
Efforts to overcome this vulnerability via structural modifications to the peptide
frequently gain proteolytic resistance at the expense of efficacy and/or the
surrounding physiological environment, thus compromising their potential as
therapeutic candidates.88,90–92 Peptoids are peptidomimetics with a capacity for
intranasal administration to the brain93,137–139 and escape the vulnerability of
peptide therapeutics to proteases via movement of the side-chain from the
a-carbon to the amide nitrogen. This modification enables peptoids to withstand
physiological challenges to structural (and therefore functional) integrity
encountered prior to reaching the site of action.3,99
Our lab has previously evaluated variants of a rationally-designed peptoid
mimic of the KLVFF hydrophobic core of Ab for their ability to modulate Ab
aggregation.99,100 One variant—JPT1a—stood apart in its capacity to not only
reduce the overall number of Ab1-40 aggregates formed, but to also alter the
morphology of formed aggregates.99 Because of the promise shown in our
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previous studies of JPT1a with Ab, we extended our investigation of JPT1a to
include chronic inflammation and RAGE expression.
As with all therapeutics, an ideal agent should maximize therapeutic efficacy
at minimal detriment to the host or patient. Recognition of RAGE as a therapeutic
target has produced various small molecule antagonists for the receptor still in
early stages of development.51 It is common for small molecule inhibitors to require
high concentrations or frequent exposure to achieve therapeutic efficacy, an
achievement that may be compromised by toxicity to the surrounding cellular
environment.71–73 The lack of upregulation of transmembrane RAGE expression
and inflammatory cytokine response with treatment of JPT1a alone (Figures 4.2,
4.3), as well as the lack of change in metabolic activity noted in the XTT assay
(Figure 4.8), show that JPT1a in itself exerts no notable harmful cellular effects in
this model. JPT1a significantly modulates RAGE expression, both when
introduced simultaneously with the proinflammatory stimulus (Figure 4.2) and
when introduced after the onset of chronic conditioning. (Figure 4.4) When
introduced

simultaneously

with

LPS,

JPT1a

prevents

upregulation

of

transmembrane RAGE in a dose-dependent manner (Figure 4.2) That this
phenomenon is not observed when JPT1a is applied to pre-conditioned cells may
allude to a change in cellular condition or inflammatory status that alters the
therapeutic range required for changes in transmembrane RAGE expression to
occur. JPT1, the chiral analogue of JPT1a, regulates RAGE expression in a similar
dose-dependent manner as observed with JPT1a when co-incubated with the
proinflammatory stimulus. (Figure 4.6) While this effect reinforces the strength of
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the core peptoid design, the overall response is not as pronounced as that noted
with JPT1a and insinuates that JPT1a’s achirality may afford some therapeutic
benefit with respect to RAGE.
JPT1a also modulates inflammatory cytokine expression when introduced
with the proinflammatory stimulus at the onset of conditioning. (Figure 4.3) This
effect, however, is absent with previously-conditioned cells (Figure 4.5).
RAGE-ligand interaction potentiates and prolongs the inflammatory response; one
possible explanation for this outcome is that more time may be required than the
24 h treatment window allotted for the previously-stimulated cells to respond to a
stimulus of reversal. Exploration of structural relevance shows that JPT1 reduces
cytokine expression in a similar manner as JPT1a (Figure 4.7); this outcome
reinforces the efficacy of the core peptoid design. However, its effect is not as
compelling as that noted with JPT1a, indicating that chirality may also have some
effect on the inflammatory cytokine response.
Chronic inflammation is a means through which a myriad of cellular
dysfunction can be introduced; targeting key checkpoints in that process, such as
RAGE, offers an avenue to stall or resolve the degenerative process. A
multifaceted approach is needed in therapeutic strategies for AD that incorporates
the previous focus on Ab with additional attention to the chronic inflammation
associated with aging. Here, we have offered a novel and versatile therapeutic in
JPT1a that interacts with Ab and impacts chronic inflammation via RAGE. These
data support further investigation of JPT1a as a therapeutic for AD.
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A

B

Figure 4.1. Structures of JPT1a and JPT1. Molecular structures of JPT1a (A)
and JPT1 (B). Courtesy of Dr. Shannon Servoss, University of Arkansas.
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Figure 4.2 JPT1a modulates transmembrane RAGE expression in a
dose-dependent manner. THP-1 macrophages were treated with JPT1a alone
( ) or in the presence of a chronic low-dose (2 ng/mL) LPS ( ) for 3 days prior
to fixation and staining for RAGE. Images acquired via confocal microscopy were
analyzed via custom MATLAB™ subroutine to determine the quantity of RAGE
present within a given volume of cells. Results within each experiment are
normalized to the positive control (2 ng/mL LPS alone), indicated by the dashed
line at 1. Significance relative to positive control is shown as *: ** p < 0.01. Error
bars indicate SEM, n = 4.
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Figure 4.3. Co-incubation
with
JPT1a
attenuates
pro-inflammatory cytokine
expression.
THP-1
macrophages were treated with
JPT1a alone ( ) or in the
presence
of
a
chronic
low-dose (2 ng/mL) LPS ( )
for 3 days prior to supernatant
harvest
and
storage.
Examination of the supernatant
via ELISA determined the
concentrations of (A) IL-1b, (B)
IL-6, and (C) IL-8. Results are
reported as a fraction of the
positive control (2 ng/mL LPS
alone) indicated by the dashed
line
at
1.0.
* p < 0.05,
** p < 0.01,
*** p < 0.001,
**** p < 0.0001 vs positive
control. Error bars indicate
SEM, n = 3 – 4.

A

B

C
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Figure 4.4. JPT1a reduces transmembrane RAGE expression in previouslystimulated cells. THP1 macrophages were treated with low-dose LPS at 2 ng/mL.
After 48 hours, half of the supernatant was removed, treated with JPT1a ( ) at
final concentrations of 25, 5, 1, and 0 μM (positive control), and then added back
to respective samples. Following an additional 24 h incubation, cells were fixed,
stained, and imaged via confocal microscopy. Images were analyzed via custom
MATLAB™ subroutine to determine the quantity of RAGE present within a given
volume of cells. Results within each experiment are normalized to the positive
control (2 ng/mL LPS alone), indicated by the dashed line at 1.0. *p<0.05, **p<0.01
vs positive control. Significance between treatments indicated as: †p<0.05. Error
bars indicate SEM, n = 4.
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Figure 4.5. JPT1a does not A
affect inflammatory cytokine
production
in
previously
stimulated macrophages. THP1
macrophages were treated with
low-dose LPS at 2 ng/mL. After 48
hours, half of the supernatant was
removed, treated with JPT1a ( )
at final concentrations of 25, 5, 1,
and 0 μM (positive control), and
then added back to respective
samples. Following an additional
24 h incubation, supernatant was
B
harvested and examined for
expression of IL-1b (A), IL-6 (B),
and IL-8 (C) via ELISA. Results
within each experiment are
normalized to the positive control
(2 ng/mL LPS alone), indicated by
the
dashed
line
at
1.0.
***p < 0.001, ****p < 0.0001 vs
positive control. Error bars
indicate
standard
deviation,
n = 2–3.
C
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Figure 4.6 JPT1 modulates transmembrane RAGE expression in a
dose-dependent manner. THP-1 macrophages were treated with JPT1 alone
( ) or in the presence of a chronic low-dose (2 ng/mL) LPS ( ) for 3 days prior
to fixation and staining for RAGE. Images acquired via confocal microscopy were
analyzed via custom MATLAB™ subroutine to determine the quantity of RAGE
present within a given volume of cells. Results within each experiment are
normalized to the positive control (2 ng/mL LPS alone), indicated by the dashed
line at 1. Error bars indicate SEM, n = 2.
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Figure 4.7. Co-incubation
with
JPT1
attenuates
pro-inflammatory
cytokine
expression.
THP-1
macrophages were treated with
JPT1 alone (
) or in the
presence of a chronic low-dose
(2 ng/mL) LPS ( ) for 3 days
prior to supernatant harvest
and storage. Examination of
the supernatant via ELISA
determined the concentrations
of (A) IL-1b, (B) IL-6, and
(C) IL-8. Results are reported
as a fraction of the positive
control (2 ng/mL LPS alone).
Results within each experiment
are normalized to the positive
control (2 ng/mL LPS alone),
indicated by the dashed line at
1.
* p < 0.05,
** p < 0.01,
*** p < 0.001, **** p < 0.0001
vs positive control. Error bars
indicate SEM; n = 2 – 4.

A

B

C
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Figure 4.8. JPT1a is non-toxic
to
THP-1
macrophages.
THP-1
macrophages
were
remained untreated ( ) or were
treated with JPT1a (
) at
concentrations ranging from 1 to
50 µM. Toxicity was evaluated
via XTT assay at (A) 2 h, (B)
4 h, and (C) 24 h determined no
change cells treated with JPT1a
relative to cells treated with the
vehicle alone. Results are
reported as a fraction of cells
treated with the vehicle alone,
as indicated by the dashed line
at 1. Error bars indicate SEM;
n = 2.

A

B

C
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CHAPTER 5:
DETERMINATION OF BINDING SPECIFICITY AND AFFINITY FOR JPT1A

5.1 Introduction
The search for novel therapeutics is always a cost-benefit analysis in which
the efficacy of the drug for its therapeutic target is weighed against the expense of
off-target binding that engenders unwanted side effects. We have identified a novel
RAGE antagonist, JPT1a, and observed in Chapter 4 its capacity to modulate
transmembrane RAGE expression and chronic inflammation. Here, we confirm the
selectivity and binding affinity of JPT1a for RAGE, which exceeds the binding
affinity of Azeliragon, a small-molecule RAGE antagonist that has completed
clinical trials.

5.2 Materials and Methods
5.2.1 Determination of selective binding between JPT1a and RAGE
JPT1a was reconstituted in DPBS to 500 µM, diluted to 10 µM with PBS
and mixed with coating buffer to achieve a final concentration of 500 nM JPT1a.
Clear, flat-bottomed 96-well plates were coated with JPT1a at this concentration.
Wells on the same plate were coated with E-cadherin or RAGE at 20, 10, 8, 5, and
1 nM to function as a calibration curve, and the plate was covered and stored
overnight at 4°C.
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To examine peptoid-RAGE binding, dilution buffer from a RAGE ELISA kit
(Aviscera Biosciences) was used to prepare samples of RAGE in concentrations
ranging from 1 to 500 nM. Coating buffer was removed from the plate and wells
were washed three times with kit-included wash buffer prior to sample application
to peptoid-coated wells; dilution buffer was applied to RAGE-coated wells. Plates
were incubated overnight at 4°C. Samples were then removed, and the plate
washed three times with wash buffer. Kit-included detection antibody was applied
to each well, and plates were placed on an orbital shaker for 2 h at 25°C. Plates
were washed three times after removal of detection antibody, treated with
kit-included anti-rabbit IgG-HRP conjugate in HRP diluent solution, and
subsequently covered and placed on an orbital shaker for 1 h at room temp. Each
well was washed four times post HRP removal; TMB substrate was prepared and
immediately applied to the covered plate for 1-2 min prior to cessation of the
colorimetric reaction via kit-included stop solution. Absorbance was assessed at
450 nm using a SpectraMax microplate reader (Molecular Devices, San Jose, CA).
The calibration curve generated from RAGE-coated wells was used to approximate
the concentration (nM) of RAGE bound on peptoid coated wells.
To examine JPT1a – E-cadherin interactions, samples of E-cadherin in
concentrations ranging from 1 to 500 nM were prepared with Assay Diluent
RD1-78 buffer from an E-cadherin ELISA kit (R&D Systems). Coating buffer was
removed from the plate and wells were washed three times with kit-included wash
buffer prior to sample application to peptoid-coated wells; Assay Diluent RD1-78
alone was applied to E-cadherin-coated wells. Plates were incubated overnight at
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4°C. Samples were then removed, and the plate was washed three times with
wash buffer. 200 µL of kit-included human E-cadherin conjugate was applied to
each well, and plates were placed on an orbital shaker for 2 h at room temperature.
Each well was washed four times post conjugate removal; 200 µL of kit-included
substrate solution was applied to wells and the plate was covered and incubated
for 1-2 min at 25°C prior to cessation of the colorimetric reaction via 50 µL of
kit-included stop solution. Absorbance was assessed at 450 nm using a
SpectraMax microplate reader (Molecular Devices, San Jose, CA). The calibration
curve generated from E-cadherin-coated wells was used to approximate the
concentration (nM) of E-cadherin bound on peptoid coated wells.
Results were analyzed in Microsoft Excel and are reported as the average
concentration of bound protein in JPT1a-coated wells as determined from the
calibration curve generated by wells coated with 20 nM RAGE or E-cadherin.
Scatchard analysis was used to estimate Kd of JPT1a for RAGE within each
experiment; the calculated concentration of RAGE bound was normalized to the
concentration of RAGE applied and reported relative to the concentration of RAGE
bound.

5.2.2 Determination of binding affinity via modified ELISA
JPT1a was reconstituted in DPBS to 500 µM and diluted to 10 µM with PBS.
Incubations were prepared using kit-included dilution buffer to contain 20 nM
RAGE and concentrations of JPT1a ranging from 0 (control) to 1000 nM. Samples
were vortexed gently to mix and incubated overnight at 4°C to reach equilibrium.
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JPT1a was also mixed with coating buffer to achieve a final concentration
of 500 nM JPT1a and used to coat two clear, flat-bottomed 96-well plates; these
plates were covered and stored overnight at 4°C. The following day, plates were
gently washed three times after removal of coating solutions. Incubations prepared
the previous day were mixed gently and applied to the first plate in triplicate. After
5 min on an orbital shaker at 25°C, samples from the first plate were quickly
removed via multichannel pipettor and applied directly to their respective wells on
the second plate; this plate was then placed on an orbital shaker for 5 min at 25°C.
Plates were washed three times immediately after sample removal and incubated
with kit-included detection antibody and anti-rabbit IgG-HRP conjugate in HRP
diluent solution with intermediate wash steps as previously described in Section
5.2.1. Fresh TMB substrate was mixed and applied directly to treated wells on each
plate for 90 sec prior to reaction cessation with kit-included stop solution.
Absorbance was assessed at 450 nm using a SpectraMax microplate reader
(Molecular Devices, San Jose, CA). Relative absorbance values between the two
plates were recorded at or below 11%, indicating that equilibrium in solution
remained undisturbed under these parameters.140–142 Subsequent experiments
evaluate affinity via the first treated.
Absorbance data was used to calculate the concentration bound/free
concentration (Equation 5.1) and bound (Equation 5.2) using the Cheng-Prussoff
method of analysis, where A0 is the absorbance of RAGE alone, Ai is the individual
absorbance at varying concentrations of JPT1a, A∞ is the absorbance of samples
with JPT1a in excess. [X] total represents the total molar concentration of assumed
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RAGE epitopes on JPT1a (1:1), and [JPT1a]total is the total concentration of JPT1a
added to each well.140–142
𝐴# − 𝐴%
[ ]
𝐴# − 𝐴& ∗ 𝑋 ,-,./
𝐴 − 𝐴%
[𝐽𝑃𝑇1𝑎],-,./ − #
[𝑋],-,./
𝐴# − 𝐴& ∗

𝐴# − 𝐴%
∗ [𝑋],-,./
𝐴# − 𝐴&

Equation 5.1

Equation 5.2

Generated data from all experiments was first assessed via Scatchard
analysis using GraphPad Prism 8.0 software, which plots specific binding as
calculated in Equation 5.2 versus the ratio of specific binding to unbound ligand as
calculated in Equation 5.1. The negative inverse of the slope produced via linear
regression is used to determine the Kd.

Points that fall outside of the 95%

prediction bands were removed as outliers. GraphPad Prism 8.0 was also used to
generate a specific binding curve to analyze data from all experiments, which plots
the relative concentration of bound RAGE (Equation 5.2) versus the concentration
of JTP1a in solution. Kd is determined as the concentration of JPT1a required to
achieve half-maximal binding.

5.3 Results
5.3.1 RAGE binds to JPT1a selectively
The concentrations of bound JPT1a-RAGE, shown in Figure 5.1A,
demonstrate a clear relationship of dose-dependence. In contrast, an absence of
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binding between JPT1a and E-cadherin, a cell adhesion molecule ubiquitously
expressed on macrophages, is observed in Figure 5.1B, reinforcing the specificity
of JPT1a for RAGE. The distinct difference in the binding relationships between
JPT1a and these two molecules demonstrate the specificity of JTP1a for RAGE.
A Scatchard plot (Figure 5.1C) was constructed from the calculated
concentration of bound RAGE and the estimated free RAGE, as determined from
absorbance values generated by RAGE-coated wells. Scatchard analysis of these
results estimates a low nanomolar affinity (Kd = 51.8 ± 7.3 nM) of JTP1a for RAGE.

5.3.1 JPT1a binds to RAGE with low nanomolar affinity
While the previous experiments approximate affinity for binding of RAGE to
JPT1a-coated plates, a better estimate of affinity is determined from binding in
solution. Examination of binding of 20 nM RAGE to concentrations of JPT1a
ranging from 0 to 1000 nM show an estimated binding affinity of 127.4 nM
(Rsq = 0.41) as examined via Scatchard plot (Figure 5.2A). Data plotted to a
specific binding curve (Figure 5.2B) approximates a Kd = 58.1 ± 19.9 nM
(Rsq = 0.69).

5.4 Discussion
The recent emergence of RAGE as a relevant therapeutic target has
brought a number of potential RAGE antagonists to the forefront, yet their practical
application as neurotherapeutics faces a number of challenges. The use of mAbs
as RAGE antagonists has shown some promise in peripheral contexts such as
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crush injury143 and neuropathic pain,144 yet antibodies are limited in their
application as neurotherapeutics for their inability to cross the blood-brain
barrier.145,146
Many proposed RAGE antagonists are small molecule inhibitors; while able
to cross the blood-brain barrier, these small molecules may induce toxicity through
their need for frequent exposure or high concentrations to be effective.71–73
TTP488, or Azeliragon, binds to RAGE with moderate affinity at 500 nM.51 In
Phase II clinical trials, high doses of the RAGE-antagonist Azeliragon produced
negative patient outcomes, yet patients that received low doses of the antagonist
demonstrate significantly improved outcomes one year later.61 Azeliragon moved
on to Phase III clinical trials because of this success, but these trials were
terminated when co-primary efficacy endpoints were not met.147 Another small
molecule RAGE antagonist, FPS-ZM1, binds to RAGE with low-nanomolar affinity.
FPS-ZM1 demonstrated low toxicity in vitro and in vivo, while enjoying some
success in ameliorating Ab-induced negative effects.51,146 However, a radiolabeled
analogue of this compound found significant nonspecific binding to white matter in
vivo.148 Very few peptide antagonists for RAGE have been studied,51 and are
ultimately limited in in vivo through their vulnerability to proteolysis.3
JPT1a is a rationally-designed peptoid mimic of the KLVFF hydrophobic
core of Ab that is attractive for its invulnerability to proteolysis. Although JPT1a
exceeds the 500 Da size attributed to small molecules, it is still quite small at
~1 kDa, and its capacity for intranasal administration facilitates passage of the
blood-brain barrier. In this study, we have demonstrated that JPT1a binds to RAGE
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selectively (Figure 5.1) and does so with low nanomolar affinity (Figure 5.2)—an
5-to-10 fold less than that of Azeliragon.51 These results support further
investigation of JPT1a as a potential therapeutic for neurodgenerative diseases
such as AD.
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A

B

C

Figure 5.1. JPT1a binds to RAGE selectively. 96-well plates coated with 500 nM
JPT1a were treated with concentrations of A) RAGE or B) E-cadherin ranging from
1 to 500 nM. Values are reported as the average concentration of bound protein
determined from all experiments. Error bars indicate SEM, n = 2—5. C) This
Scatchard plot for RAGE binding represents data generated from one trial; an
average Kd = 51.8 ± 7.3 nM was calculated from n = 3.
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A

B

Figure 5.2. JPT1a binds to RAGE with low nanomolar affinity. 96-well plates
coated with 500 nM JPT1a were treated with overnight incubations containing
20 nM RAGE and JPT1a in concentrations ranging from 0 nM to 1000 nM.
Absorbance values were used to calculate relative [RAGE]bound and [RAGE]free via
the Cheng-Prussoff method.140–142 A) Experimental values from n = 1 (●), n = 2
(■), and n = 3 ( ◆) were plotted via Scatchard plot, which estimates a binding
affinity of JPT1a for RAGE of 127.4 nM. Black dashed lines indicate
95% confidence interval, and gray dashed lines indicate 95% prediction interval,
n = 3. B) Data was also analyzed via plot of specific binding (one epitope) to yield
Kd of 58.1 ± 19.9 nM. Dashed lines indicate 95% confidence interval, n = 3.
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CHAPTER 6:
CONCLUSIONS
A rapidly aging population impresses the need for effective therapeutics for
aging-associated neurodegenerative diseases such as AD. It is well-established
that the formation and accumulation of Ab aggregate species provoke
neurotoxicity, and the last several decades of proposed AD therapies have been
appraised for their ability to mitigate this toxicity in some way.149,150 Yet AD
therapies that aim to inhibit Ab production and/or aggregate formation have yielded
little success in clinical trials,14 suggesting that this strategy is insufficient.
Meanwhile, the revelation of aging as an increase in the basal state of inflammation
has brought chronic inflammation to the forefront alongside Ab for therapeutic
strategies in neurodegenerative disease.
The first aim of this study was to design and develop an in vitro cellular
model that allows the exploration of potential AD therapeutics within the context of
chronic inflammation. As discussed in Chapter 3, this model achieved this
objective in several ways. First, the use of RAGE is a strategic target for both Ab
and chronic inflammation. RAGE is a focal point at which Ab and inflammation
intersect, as Ab is a ligand for RAGE and RAGE mediates several Ab-associated
responses that contribute to AD pathology, including promotion of vascular
leakage and influx of Ab into the brain, mediation of Ab-induced oxidative stress,
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mediation of AGE-induced hyperphosphorylation of tau, and participation in
Ab-mediated neuronal apoptosis.43,56,58,120 RAGE is also integral in the onset,
amplification, and evolution of persistent inflammation145,151–153 and is featured in
the progression of aging- and inflammation-associated diseases that also
represent an increased risk in AD, such as Type II diabetes and cardiovascular
disease.56,57 That upregulation of transmembrane RAGE requires the chronic
presence of its ligands reinforces its validity as a point of evaluation within a chronic
model. Evaluation of the coincident inflammatory cytokine response bolsters the
results reported with transmembrane RAGE expression. The proposed model
achieves mimicry of key aspects of immunosenescence alongside upregulation of
RAGE, evidenced by the altered response to acute stimulus in the expression of
IL-1b, IL-6, IL-10, and TNF-a. The DVE component of the model illustrates the
relevance of a static external cellular environment and buildup of cellular product
in chronic conditioning.
Also presented in this study is JPT1a, a potential achiral Ab-mimic peptoid
therapeutic for AD that modulates transmembrane RAGE expression and the
accompanying inflammatory cytokine response. From this study, JPT1a appears
most effective when introduced at the onset of inflammation, as demonstrated by
its ability to modulate RAGE expression and inflammatory cytokine response with
co-incubation of JPT1a and the proinflammatory stimulus. Although the former is
also achieved with previously-stimulated cells, cytokine response remains
unaffected; however, an exposure time greater than the allotted 24 h could
produce a different outcome. The core peptoid design is validated through chiral
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JPT1’s capacity to also prevent upregulation of transmembrane RAGE and the
concurrent

inflammatory

cytokine

response

with

co-incubation

of

the

proinflammatory stimulus.
Finally, the selectivity of JPT1a for RAGE was confirmed through an evident
dose-dependent binding curve generated via direct binding of RAGE on
JPT1a-coated plates, as well as the lack of binding visualized with E-cadherin.
Definitive binding affinity of JPT1a for RAGE was determined from equilibrium
attained in solution, and a low nanomolar binding affinity is reported.
We have here introduced a potential therapeutic that modulates two primary
contributive factors to AD, Ab (through previous research) and chronic
inflammation via RAGE. The binding affinity observed for JPT1A-RAGE is a full 5to-10 fold lower than that reported for Azeliragon, the only RAGE antagonist that
has entered clinical trials. These data support the continued investigation of JPT1a
as a potential therapeutic for AD.
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CHAPTER 7:
FUTURE PERSPECTIVES
The cellular inflammatory model proposed in this study facilitates the
exploration of novel therapeutics in the context of chronic inflammation. While
examination via cellular model is a critical step in drug discovery and mechanistic
understanding, drug metabolism, toxicity, and efficacy must ultimately be
characterized in vivo. Several transgenic murine models for AD exist and are
frequently employed to evaluate potential therapeutics, but murine models to
examine the effects aging have also become more eminent. Mice engineered to
carry senescent reporters, such as knockin p16+/LUC and transgenic p16-3MR and
p16-INK- ATTAC mice, would facilitate investigation of JPT1a as a modulator of
chronic inflammation in vivo.
The chronic inflammation associated with aging is complex and may be
induced through RAGE via multiple ligands in addition to Ab, such as advanced
glycation end-products, S100/calgranulins, and high mobility group box
1(HMGB1).51,146,152 We have shown here that JPT1a binds to RAGE selectively
and established JPT1a’s interaction with Ab through previous research.99
Discovery of JPT1a as a multi-ligand RAGE antagonist would likely boost its
efficacy in vivo and would likely diminish the therapeutic dose required for efficacy,
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making it an even more attractive therapeutic candidate for neurodegenerative
disease.
RAGE

antagonists

also

have

potential

applications

outside

of

neurodegeneration. RAGE has received recent attention for its potential
therapeutic in chronic obstructive pulmonary disease (COPD) and other
inflammatory disorders of the respiratory tract.154 The recent opioid crisis in the
United States has affected many Americans personally, and recent applications of
RAGE antagonists in neuropathic pain144 and crush injuries143 opens an entirely
new area of potential for JPT1a. The factors that make the peptoid JPT1a attractive
as a potential therapeutic, such as its invulnerability to proteolysis, high mobility,
and specificity, are very likely applicable to these other contexts as well and should
be explored.
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APPENDIX A: MATLAB CODE
The code below was designed by Nick van der Munnik. This script calls the
“ragepervolp2” function which determines the volume of RAGE co-localized with
DAPI or phalloidin expressed relative to the volume of DAPI or phalloidin
occupied to determine the average RAGE per cell.

1.

ragevalper

2.%%% Image Requirements %%%
3.% -Must be obtained with the same lasers and magnification used to
4.% calibrate this code
5.% -Image names must be in the following format
6.
7.%
"ragexx.tif"
8.
9.% -All images must be in the current file folder
10.
% -Program assumes all image files have the same dimensions
11.
12.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
13.
% Specify the number of samples you wish to process
14.
15.
numsam=30;
16.
17.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
18.
19.
20.
DAPI=[];
21.
PHAL=[];
22.
RAGE=[];
23.
Fig=[];
24.
dataoutput=double(zeros(numsam,1));
25.
index=uint32(zeros(numsam,1));
26.
starttime=clock;
27.
hrs=starttime(4);
28.
mins=starttime(5);
29.
secs=starttime(6);
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30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.

for i=1:numsam
DAPI=uint8(imread(strcat('rage',num2str(i),'.tif'),1));
PHAL=uint8(imread(strcat('rage',num2str(i),'.tif'),2));
RAGE=uint8(imread(strcat('rage',num2str(i),'.tif'),3));
[dataoutput(i),Fig]=ragepervolp2(DAPI,PHAL,RAGE);
index(i,1)=i;
imwrite(Fig,strcat('SweetAss2014/Desktop/LNP3419all/MLImage',num2str(i),'.tif'));
figure
imshow(Fig)
end
endtime=clock;
hre=endtime(4);
mine=endtime(5);
sece=endtime(6);
avg=double((((hre*3600)+(mine*60)+sece)-((hrs*3600)+(mins*60)+secs))/numsam);
avg=avg/60;
fprintf('average time per sample (minutes)')
avg
fprintf(' Index Cells Avg RAGE per Cell')
index=double(index);
dataoutput=[index dataoutput]

2. ragepervolp2
function [data,output]=ragepervolp2(D,P,R)
dim=size(D);
rdim=dim(1,1);
cdim=dim(1,2);
A=uint16(zeros(rdim,cdim));
B=uint8(zeros(rdim,cdim));
Dstore=D;
Pstore=P;
Rstore=R;
C=uint8(zeros(rdim,cdim));
Dthresh=30;
Pthresh=90;
rsum=uint32(0);
acnt=uint32(0);
for i=1:rdim
for j=1:cdim
if P(i,j)>=Pthresh || D(i,j)>=Dthresh
acnt=acnt+1;
rsum=rsum+uint32(R(i,j));
C(i,j)=255;
else
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C(i,j)=0;
end
end
end
output=C;
data=double(rsum)/double(acnt)
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